New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 21, 2012
07:38 EDTHZNPHorizon Pharma to receive approval from UK MHRA
Horizon Pharma announced that the United Kingdom Medicines and Healthcare products Regulatory Agency, or MHRA, based on the favorable recommendation of their Commission on Human Medicines (CHM), will grant a Marketing Authorization for Duexis, pending review of updated licensing documents which the Company has provided to the MHRA. The MA of Duexis is for the treatment of osteoarthritis, or OA, rheumatoid arthritis, or RA, and ankylosing spondylitis, or AS, and to decrease the risk of developing upper gastrointestinal ulcers. Duexis is approved and available in the United States.
News For HZNP From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 23, 2014
07:42 EDTHZNPPOZEN receives three patents from USPTO
POZEN (POZN) announced that it has received three patents from the United States Patent and Trademark Office, entitled “Pharmaceutical Compositions for the Coordinated Delivery of NSAIDs” that cover the U.S. approved product VIMOVO. All three patents are expected to expire in 2022. Horizon Pharma (HZNP), which holds the U.S. NDA for VIMOVO, and POZEN plan to list U.S. patents 8,858,996 and 8,852,636 in the FDA's Approved Drug Products with Therapeutic Equivalence Evaluations, or Orange Book.
October 17, 2014
07:45 EDTHZNPHorizon Pharma to host conference call
Subscribe for More Information
07:04 EDTHZNPHorizon Pharma acquires U.S. rights to PENNSAID 2% for $45M
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use